JP2020517239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517239A5 JP2020517239A5 JP2019556600A JP2019556600A JP2020517239A5 JP 2020517239 A5 JP2020517239 A5 JP 2020517239A5 JP 2019556600 A JP2019556600 A JP 2019556600A JP 2019556600 A JP2019556600 A JP 2019556600A JP 2020517239 A5 JP2020517239 A5 JP 2020517239A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- antibody
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 150000001413 amino acids Chemical group 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960001153 serine Drugs 0.000 claims 2
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 229930182821 L-proline Natural products 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005264 laryngeal carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 229960002429 proline Drugs 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022178282A JP2023025003A (ja) | 2017-04-18 | 2022-11-07 | 抗ｐｄ－ｌ１抗体とその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2017028206 | 2017-04-18 | ||
| USPCT/US2017/028206 | 2017-04-18 | ||
| PCT/US2018/028206 WO2018195226A1 (en) | 2017-04-18 | 2018-04-18 | Anti-pd-l1 antibody and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178282A Division JP2023025003A (ja) | 2017-04-18 | 2022-11-07 | 抗ｐｄ－ｌ１抗体とその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517239A JP2020517239A (ja) | 2020-06-18 |
| JP2020517239A5 true JP2020517239A5 (enExample) | 2021-05-13 |
Family
ID=63856823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556600A Pending JP2020517239A (ja) | 2017-04-18 | 2018-04-18 | 抗ｐｄ−ｌ１抗体とその使用 |
| JP2022178282A Pending JP2023025003A (ja) | 2017-04-18 | 2022-11-07 | 抗ｐｄ－ｌ１抗体とその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178282A Pending JP2023025003A (ja) | 2017-04-18 | 2022-11-07 | 抗ｐｄ－ｌ１抗体とその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210115143A1 (enExample) |
| EP (1) | EP3612565A4 (enExample) |
| JP (2) | JP2020517239A (enExample) |
| KR (1) | KR102323960B1 (enExample) |
| CN (1) | CN110856446A (enExample) |
| AU (1) | AU2018256392B2 (enExample) |
| BR (1) | BR112019021828B1 (enExample) |
| CA (1) | CA3059447A1 (enExample) |
| CL (1) | CL2019002953A1 (enExample) |
| CO (1) | CO2019012118A2 (enExample) |
| EA (1) | EA201900443A1 (enExample) |
| MA (1) | MA50038A (enExample) |
| MX (1) | MX2019012461A (enExample) |
| MY (1) | MY199319A (enExample) |
| PH (1) | PH12019502302A1 (enExample) |
| SG (1) | SG11201909041SA (enExample) |
| WO (1) | WO2018195226A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| JP7497351B2 (ja) * | 2018-11-13 | 2024-06-10 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | チェックポイント分子に対する多重特異性結合性構築物およびその使用 |
| CN113646330A (zh) | 2018-11-14 | 2021-11-12 | 鲁比克治疗股份有限公司 | 工程化cd25多肽及其用途 |
| CA3120096A1 (en) | 2018-11-14 | 2020-05-22 | Rubryc Therapeutics, Inc. | Cd25 antibodies |
| CN109929037B (zh) | 2019-04-01 | 2023-03-17 | 华博生物医药技术（上海）有限公司 | 针对程序性死亡配体的结合物及其应用 |
| JP7302010B2 (ja) * | 2019-04-11 | 2023-07-03 | スクリップス コリア アンチボディ インスティチュート | プログラム細胞死タンパク質リガンド－１（ｐｄ－ｌ１）に対する抗体及びその用途 |
| SG11202103000WA (en) * | 2019-04-26 | 2021-04-29 | I Mab Biopharma Us Ltd | Human pd-l1 antibodies |
| US20210403568A1 (en) * | 2020-06-29 | 2021-12-30 | Cai Gu Huang | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
| CA3187850A1 (en) | 2020-08-04 | 2022-02-10 | Bryan Glaser | Pd-l1 binding agents and uses thereof |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| WO2023046113A1 (zh) * | 2021-09-24 | 2023-03-30 | 广东菲鹏制药股份有限公司 | 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用 |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE454137T1 (de) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| MX356367B (es) * | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| US10202454B2 (en) * | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| WO2015103602A1 (en) * | 2014-01-06 | 2015-07-09 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| CA3265373A1 (en) * | 2014-02-20 | 2025-10-30 | H. Lundbeck A/S | Anti-acth antibodies and use thereof |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| MA42971A (fr) * | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| JP7011657B2 (ja) * | 2016-10-30 | 2022-02-10 | シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド | 抗ｐｄ－ｌ１抗体および変異型 |
-
2018
- 2018-04-18 EA EA201900443A patent/EA201900443A1/ru unknown
- 2018-04-18 AU AU2018256392A patent/AU2018256392B2/en not_active Ceased
- 2018-04-18 MX MX2019012461A patent/MX2019012461A/es unknown
- 2018-04-18 US US16/606,647 patent/US20210115143A1/en not_active Abandoned
- 2018-04-18 MA MA050038A patent/MA50038A/fr unknown
- 2018-04-18 JP JP2019556600A patent/JP2020517239A/ja active Pending
- 2018-04-18 CA CA3059447A patent/CA3059447A1/en active Pending
- 2018-04-18 EP EP18788069.5A patent/EP3612565A4/en not_active Withdrawn
- 2018-04-18 CN CN201880025898.4A patent/CN110856446A/zh active Pending
- 2018-04-18 KR KR1020197032419A patent/KR102323960B1/ko not_active Expired - Fee Related
- 2018-04-18 WO PCT/US2018/028206 patent/WO2018195226A1/en not_active Ceased
- 2018-04-18 SG SG11201909041S patent/SG11201909041SA/en unknown
- 2018-04-18 MY MYPI2019006142A patent/MY199319A/en unknown
- 2018-04-18 BR BR112019021828-9A patent/BR112019021828B1/pt not_active IP Right Cessation
-
2019
- 2019-10-07 PH PH12019502302A patent/PH12019502302A1/en unknown
- 2019-10-16 CL CL2019002953A patent/CL2019002953A1/es unknown
- 2019-10-29 CO CONC2019/0012118A patent/CO2019012118A2/es unknown
-
2022
- 2022-11-07 JP JP2022178282A patent/JP2023025003A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507135A5 (enExample) | ||
| JP2025163055A5 (enExample) | ||
| JP2019501883A5 (enExample) | ||
| JP2022515318A5 (enExample) | ||
| JP2021522162A5 (enExample) | ||
| JP2019502405A5 (enExample) | ||
| JP2022530404A5 (enExample) | ||
| JP2021502104A5 (enExample) | ||
| JP2025069432A5 (enExample) | ||
| JP2023543493A5 (enExample) | ||
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP2020501531A5 (enExample) | ||
| RU2018139339A (ru) | Новые биспецифические полипептиды против cd137 | |
| JP2017531028A5 (enExample) | ||
| JP2018512138A5 (enExample) | ||
| JP2009521496A5 (enExample) | ||
| JP2022532173A5 (enExample) | ||
| JP2010531140A5 (enExample) | ||
| RU2009149205A (ru) | Моноклональные антитела против клаудина-18 для лечения рака | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2024119853A5 (enExample) | ||
| JP2007515165A5 (enExample) | ||
| JP2022545741A5 (enExample) | ||
| JP2020533965A5 (enExample) | ||
| JP2020502233A5 (enExample) |